ARTICLE | Clinical News

Arimidex anastrozole: Phase III data; marketed to treat advanced breast cancer that has progressed following tamoxifen therapy

December 20, 1999 8:00 AM UTC

AstraZeneca presented previously reported data from its European and North American TARGET studies involving a total of 1,021 patients showing that overall, women treated with the company's Nolvadex t...